RT Journal Article
T1 Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry.
A1 Wild, Mirjam G
A1 Lubos, Edith
A1 Cruz-Gonzalez, Ignacio
A1 Amat-Santos, Ignacio
A1 Ancona, Marco
A1 Andreas, Martin
A1 Boeder, Niklas F
A1 Butter, Christian
A1 Carrasco-Chinchilla, Fernando
A1 Estevez-Loureiro, Rodrigo
A1 Kempfert, Jörg
A1 Köll, Benedikt
A1 Montorfano, Matteo
A1 Nef, Holger M
A1 Toggweiler, Stefan
A1 Unbehaun, Axel
A1 Werner, Paul
A1 Windecker, Stephan
A1 Praz, Fabien
K1 Heart failure
K1 Heart valve diseases
K1 Stent
K1 Tricuspid valve
K1 Tricuspid valve insufficiency
AB Patients with severe tricuspid regurgitation present late and are often ineligible for surgery or transcatheter repair systems. Transfemoral venous implantation of a bicaval valved stent has been proposed as therapeutic option in selected patients. The aim of this study was to summarize the early procedural and clinical outcomes of the novel TRICENTO system for the treatment of patients with symptomatic severe tricuspid regurgitation. All consecutive patients treated with the custom-made TRICENTO implant at the participating centers were included in this retrospective multicentre registry. A total of 21 high-risk patients (mean age 76±7 years; 67% female) with severe or higher grade tricuspid regurgitation were analyzed. The majority of the patients were in New York Heart Association class III/IV (95%), had peripheral edema (95%), and previous hospitalization for right heart failure (67%). Technical success was 100%, and there was no case of in-hospital mortality. During follow-up (median 61 days), symptomatic improvement was observed (65% in New York Heart Association class I/II; P The present data indicate the feasibility of transfemoral bicaval valved stent implantation for the treatment of severe tricuspid regurgitation. Functional improvement and signs of right ventricular reverse remodeling were observed. Stent fractures did not impair valve function, but require refinement of prosthesis design and careful assessment of eligibility criteria.
PB Lippincott Williams & Wilkins
YR 2022
FD 2022-03-03
LK http://hdl.handle.net/10668/20195
UL http://hdl.handle.net/10668/20195
LA en
NO Wild MG, Lubos E, Cruz-Gonzalez I, Amat-Santos I, Ancona M, Andreas M, et al. Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry. Circ Cardiovasc Interv. 2022 Mar;15(3):e011302
DS RISalud
RD Apr 8, 2025